Whitepaper: Profiling oncology candidates
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
In this whitepaper, we describe a profiling strategy that includes both in vitro and in vivo approaches to characterise sorafenib, an ATP-competitive multi-kinase inhibitor with clinical applications in multiple cancer types. Data for vemurafenib, an anti-neoplastic B-Raf kinase inhibitor, is also included to highlight how profiling compounds can shed light onto potentially different applications in the clinic.
Related content from this organisation
- Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts
- Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes
- Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes
- Hit discovery for GPCRs: HTS or virtual screens?
- Paradigm Shift in Drug Discovery: Discover Small Molecule Degraders Using E3scan™ Technology Platform